Poland· PL-100300779
Lonquex
A lipegfilgrastim product containing lipegfilgrastimum, registered in Poland by Teva B.V.. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lipegfilgrastim is registered in 12 of 19 countries.
Countries holding a registration under ATC L03AA14 (lipegfilgrastim), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Lipegfilgrastim · ATC L03AA14
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Lipegfilgrastimum
- Manufacturer
- Teva B.V.
- Country
- Poland (PL)
- ATC code
- L03AA14
- ATC class
- Lipegfilgrastim
- Defined daily dose
- 0.3 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991072469
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lipegfilgrastim in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandLonquex 6 mg/0.6 ml solution for injectionTeva B.V.
- CzechiaLONQUEXTeva B.V., Haarlem
- SpainLONQUEX 6 MG/0,6 ML SOLUCION INYECTABLETeva B.V.
- BelgiumLonquex 6 mg/0.6 mlTeva
- IcelandLonquexTeva B.V.*
- NorwayLonquexTeva B.V.
- SwedenLonquex 6 mg/0,6 ml Injektionsvätska, lösningTeva B.V.
- FinlandLonquexAbacus Medicine A/S
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Lonquex
- Iceland · Lonquex
- Liechtenstein · Lonquex
- Norway · Lonquex
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/750cdeac-135b-4214-9df2-15fabd8b4b72 GET /v1/drugs/750cdeac-135b-4214-9df2-15fabd8b4b72?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "6 mg/0,6 ml",
"packaging": "05909991072469 ¦ Rpz ¦ EU/1/13/856/001;EU/1/13/856/002 ¦ 85308\n1 amp.-strzyk. 0,6 ml\nRpz ¦ EU/1/13/856/003 ¦ 152645\n4 amp.-strzyk. 6 ml\nRpz ¦ EU/1/13/856/004 ¦ 152646\n6 fiol. 6 ml\nRpz ¦ EU/1/13/856/005 ¦ 152647\n1 fiolka 6 ml",
"substance": "Lipegfilgrastim 6 mg",
"common_name": "Lipegfilgrastimum",
"pl_product_id": "100300779",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about lipegfilgrastim.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.